Efficacy of lisdexamfetamine dimesylate for promoting occupational success in adolescents and young adults with attention-deficit/hyperactivity disorder.
Chanelle T GordonGregory A FabianoKevin F HulmeSandro M SodanoMichael AdragnaRachel LimSamantha StanfordLeah JanikowskiBradley BufaloZulema RodriguezDenise SwiatekPublished in: Experimental and clinical psychopharmacology (2020)
There has been a lack of research on the third area of impairment noted in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition-"occupational functioning." It is important to understand the impact of common treatments for attention-deficit/hyperactivity disorder (ADHD) in occupational settings. Twenty individuals with ADHD between ages 16 and 25 participated in a double-blind, placebo controlled evaluation of 40 mg lisdexamfetamine dimesylate in a setting designed to approximate a restaurant workplace with associated, simulated food delivery. Outcome measures included ratings of performance, as well as behavioral productivity. Results indicated that participants completed more workplace tasks when on medication, relative to placebo. Ratings of job application quality, job interview performance, and delivery outcomes were not significantly different on medication versus placebo. These results suggest positive effects of medication in a workplace environment, but also a need for study of additional interventions to support workplace-related behavior and functioning. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
Keyphrases
- attention deficit hyperactivity disorder
- autism spectrum disorder
- working memory
- placebo controlled
- adverse drug
- double blind
- health promotion
- healthcare
- phase iii
- social support
- squamous cell carcinoma
- skeletal muscle
- clinical trial
- type diabetes
- metabolic syndrome
- quality improvement
- radiation therapy
- electronic health record
- human health
- open label